Search
for
Sort by
Research 30 of 376
- Abstract 1677: Epithelial hyperplasia induced by a selective B-Raf inhibitor, WYE-130600
- The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
- Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
- Sorafenib-induced eruption resembling pityriasis rubra pilaris
- Cutaneous adverse effects of targeted therapies
- 329 Mechanisms of Cutaneous Adverse Events during Targeted Cancer Therapy
- Retinoid-mediated stimulation of steroid sulfatase activity in myeloid leukemic cell lines requires RARα and RXR and involves the phosphoinositide 3-kinase and ERK-MAP kinase pathways
- Self‐Assembled Peptide Hydrogels Loaded with Umbilical Cord‐Derived Mesenchymal Stem Cells Repairing Injured Endometrium and Restoring Fertility
- Biological therapy in the treatment of melanoma
- From bench to babies – drug development for male subfertility
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
- Purified Vitexin Compound 1 Inhibits UVA-Induced Cellular Senescence in Human Dermal Fibroblasts by Binding Mitogen-Activated Protein Kinase 1
- 696 MEK and BRAF inhibitors augment the production and accumulation of sebum in hamster sebocytes
- BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer
- Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review)
- Management of Toxicities of Targeted Therapies
- Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects
- 801 TEC family kinase inhibitors as a novel class of therapeutics in alopecia areata
- B-Raf and C-Raf Are Required for Melanocyte Stem Cell Self-Maintenance
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Cancer Treatments and Alopecia: A Systematic Review
- Dermatologic Adverse Events from Cancer Treatments